The Effectiveness of a Health Promotion Program for Older People With Post-Covid-19 Sarcopenia

NCT06211686 | Unknown DMC

• 2 other identifiers: MURA2023/9182023/918
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to investigate the prevalence of sarcopenia in older people with post-COVID-19 living in Ratchatewi district, Bangkok and to test the effectiveness of health promotion program for older people with post-COVID-19 Sarcopenia. The main questions it aim to answer are: • How many is the prevalence of sarcopenia in older people with post-COVID-19 living in Ratchatewi district, Bangkok? • Can the health promotion program improve muscle mass and muscle strength in older people with post-COVID-19 Sarcopenia ? Participants will be asked eating protein supplement one scoop /day and exercising 2 times/week for 3 months.

Conditions

Post COVID-19 Condition

Keywords

Sarcopenia; Older people; Health Promotion Program; Post COVID-19

Outcome Measures

Primary Outcomes (3)

• Muscle mass

  Muscle mass will be measured using BIA and calf circumference in kilograms.

  3 months

• Muscle strength

  Muscle strength will be assessed using hand grip strength in kilograms.

  3 motnhs

• Physical fitness

  Physical fitness will be measured using the Five Times Sit to Stand Test (FTSST) in second.

  3 months

Secondary Outcomes (1)

• Prevalence of sarcopenia

  3 months

Study Arms (1)

Protein supplement and Resistance exercise

EXPERIMENTAL

Other: Protein powder and Resistance exercise

Interventions

Protein powder and Resistance exercise OTHER

1. Protein powder supplementation 25-30 g/day 2. Resistance exercise 2 time/week

Protein supplement and Resistance exercise

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Older people with post-COVID-19 sarcopenia aged more than and equal 60 years
• No disabilities
• Able to read, write and communicate Thai langue
• Live in Bangkok
• Moderate post-covid-19 state defined by Thai version of the COVID-19 Yorkshire Rehabilitation Scale
• No soy protein allergy
• Sign inform consent

You may not qualify if:

• Severe post-covid-19 state defined by Thai version of the COVID-19 Yorkshire Rehabilitation Scale and complicated health problems
• Disabilities
• Unable to read, write and communicate Thai langue
• Soy protein allergy
• CKD 4 and CKD 5
• Deny or withdraw from project

Sponsors & Collaborators

• Mahidol University: lead
• National Health Security Office, Thailand: collaborator

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Central Study Contacts

Wanabhorn Tongchom, Doctoral

CONTACT

022012652; wanabhorntc@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle investigator

Model Details: Phase I: Descriptive survey research Phase II: Quasi-experimental research

Study Record Dates

• First Submitted: December 28, 2023
• First Posted: January 18, 2024
• Study Start: February 1, 2024
• Primary Completion: December 1, 2024
• Study Completion: December 1, 2024
• Last Updated: January 18, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share